Free Trial

Establishment Labs Q1 2023 Earnings Report

Establishment Labs logo
$32.30 -1.56 (-4.61%)
As of 04:00 PM Eastern

Establishment Labs EPS Results

Actual EPS
-$0.48
Consensus EPS
-$0.72
Beat/Miss
Beat by +$0.24
One Year Ago EPS
N/A

Establishment Labs Revenue Results

Actual Revenue
$46.52 million
Expected Revenue
$45.75 million
Beat/Miss
Beat by +$770.00 thousand
YoY Revenue Growth
N/A

Establishment Labs Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Establishment Labs Earnings Headlines

TD Cowen Keeps Their Buy Rating on Establishment Labs Holdings (ESTA)
Trump Treasure April 19
Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…
Establishment Labs price target lowered to $60 from $75 at TD Cowen
See More Establishment Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Establishment Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Establishment Labs and other key companies, straight to your email.

About Establishment Labs

Establishment Labs (NASDAQ:ESTA), a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

View Establishment Labs Profile

More Earnings Resources from MarketBeat